Study of the half effective dose of nicardipine for the prevention of posterior pituitary hormone-induced cardiovascular adverse effects in patients undergoing laparoscopic myomectomy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051320

Enrollment

Unknown

Registered

2021-09-20

Start date

2021-10-06

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine fibroids

Interventions

Group 1:Use nicardipine

Eligibility

Sex/Gender

Female

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients scheduled for elective laparoscopic hysterectomy for uterine fibroid removal. ASA class I or II. Age between 18 and 55 years. BMI ranging from 18 to 29 kg/m²

Exclusion criteria

Exclusion criteria: Patients with communication difficulties. Obesity (BMI > 30 kg/m²). Presence of five or more major uterine fibroids. Largest fibroid diameter exceeding 10 cm. Significant diseases affecting vital organs or systems such as ischemic heart disease, congestive heart failure, cerebrovascular disease, renal vascular disease, hypertension, etc. Severe intra-abdominal adhesions. Known allergy to bovine products. Individuals who refuse to participate in the trial.

Design outcomes

Primary

Measure	Time frame
Invasive arterial pressure;Heart rate;	—

Secondary

Measure	Time frame
ST segment;	—

Countries

China

Contacts

Public ContactWang Tingting

Changning Maternity and Infant Health Hospital

ti3wt@163.com+86 135 6441 9229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026